Atossa Genetics Inc. to Raise Approximately $6,220,000 from Institutional Healthcare Investors Seattle, Washington

Atossa Genetics Inc.

to Raise Approximately $6,220,000 from

Institutional Healthcare Investors

Seattle, Washington - June 5,

2015 - Atossa Genetics Inc. (Nasdaq: ATOS) (the "Company" or "Atossa") today announced

it priced an offering to raise approximately $6,220,000 through the sale of approximately 1.83 million shares of common stock

and pre-funded warrants to acquire approximately 3.61 million additional shares of common stock. The offering has been made to

two institutional healthcare investors, with the shares being sold at a price of $1.15 per share, and the pre-funded warrants

being sold at a price of $1.14 per warrant, payable at closing.

Roth Capital Partners served as lead placement

agent for the offering. Dawson James Securities, Inc. served as co-placement agent for the offering. After placement agent fees

and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $5.6 million.

The offering is expected to close on or about June 10, 2015, subject to customary closing conditions.

Atossa intends to use the net proceeds

from the offering for general corporate purposes, funding its future clinical trials and for general and administrative expenses.

The securities are being offered pursuant

to a shelf registration statement (File No. 333-192390), including a base prospectus, which was declared effective by the United

States Securities and Exchange Commission (the "SEC") on November 29, 2013. A prospectus supplement relating to the

offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov.

This press release shall not constitute

an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any

state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification

under the securities laws of any such state or other jurisdiction. Copies of the prospectus supplement and accompanying base prospectus

relating to this offering may be obtained from Roth Capital Partners, LLC, 888 San Clemente, Newport Beach, CA 92660, (800) 678-9147

or email: rothecm@roth.com or by accessing the SEC's website, www.sec.gov.

Steven C. Quay, M.D., Ph.D.

President & Chief Executive Officer

Atossa Genetics Inc.

Phone: (800) 351-3902

Chief Financial Officer, General Counsel and Secretary

Atossa Genetics Inc.

Phone: (800) 351-3902

Investor Relations Contact

Garden City, NY 11530

Office: 516.222.2560